SecBot SecBot
SECBOTREPLAY Home › Report › EVAX

EVAX · Evaxion presented new preclinical data at the International Herpesvirus…

Evaxion · PRESS-RELEASE filed Jul 12, 2026 at 09:30 ET

At the news

NEUTRALIMPACT 3/10

PRESS-RELEASE filed Jul 12, 2026 at 09:30 ET

Evaxion presented new preclinical data at the International Herpesvirus Workshop 2026 for its CMV vaccine program EVX-V1, showing AI-discovered T-cell epitopes improved control of acute infection, latency, and reactivation in CMV-infected mice. The data support the multi-component vaccine concept but is preclinical, no new clinical milestones, no regulatory action, and no financial figures were disclosed in the press release.

  • Data presented at International Herpesvirus Workshop 2026 in Montreal
  • New data show AI-discovered T-cell epitopes improved control of acute infection, latency, and reactivation in CMV-infected mice
  • EVX-V1 combines novel AI-discovered B-cell and T-cell antigens with AI-optimized versions of established CMV vaccine antigens
  • No licensed CMV vaccine exists currently

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access